Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard therapy.
Gastric Cancer
DRUG: ONO-4538|DRUG: Placebo
Overall survival, Up to study completion (estimated time frame: 30 months), every 2 weeks in principle
Progression-free survival, Up to study completion (estimated time frame: 30 months), every 2 weeks in principle|Objective response rate, Up to study completion (estimated time frame: 30 months), every 6 weeks in principle|Duration of response, Up to study completion (estimated time frame: 30 months), every 6 weeks in principle|Safety will be analyzed through the incidence of adverse events, serious adverse events, Continuously throughout study treatment and up to 28 days from last dose|Safety will be analyzed through the incidence of laboratory abnormalities, Continuously throughout study treatment and up to 28 days from last dose
The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard therapy.